Salman L, et al. - Authors evaluated 79 study participants from January 2005 to June 2017 to assess the effect of neoadjuvant chemotherapy (NACT) treatment alterations on surgical consequences and progression-free survival (PFS) in females with ovarian carcinoma. They included a delay in treatment, change in chemotherapy, and dose reduction as NACT modifications. They observed no influence of NACT treatment modifications on surgical outcome and PFS and no intergroup differences with respect to age at diagnosis and stage of the disease. They did, however, note similar radiologic complete response rates and optimal cytoreduction rates among study participants.